期刊文献+

替比夫定治疗慢性乙型肝炎患者52周HBV耐药分析 被引量:1

Analysis of the genotypic resistance of HBV in patients with chronic hepatitis B infection treated with telbivudine for 52 weeks
收藏 分享 导出
摘要 目的研究替比夫定(LdT)治疗基因C型慢性乙型肝炎(CHB)病人52周HBV耐药情况及变异位点。方法初治的基因C型CHB 40例(治疗前应用核酸扩增荧光定量及测序法进行耐药突变检测,HBV-P区均未测到耐药变异),给予LdT 600mg qd治疗52周。病人在治疗前及治疗后每3个月均做肝功、HBV血清学指标、HBV DNA定量检测(COBAS?TaqMan?,最低检测限300copies/ml)。选择LdT治疗52周HBV DNA〉1 000copies/ml者,对其36周及52周血清再次进行HBV-P区耐药突变检测。结果 21例(52.5%)病人HBV DNA〈300copies/ml,16例(40.0%)HBV DNA〉1 000copies/ml,3例(7.5%)HBeAg阳性病人发生HBeAg血清学转换。10例(25.0%)52周检测到HBV-P区耐药突变,其中2例rtA181T变异,7例rtM204I变异,1例rtM204I+L180M变异。结论初治CHB病人,尤其是基线HBV DNA定量较高者,对LdT治疗有较高的耐药率,HBV基因可发生1个或多个位点耐药变异,rtM204I是LdT耐药的主要突变位点。 Objective The aim of this study was to determine the incidence of genotypic resistance(GR) and analyze the amino acid substitutions associated with telbivudine(LdT) resistance in week 52 in patients with genotype C hepatitis B who were treated with LdT.Methods Subjects were 40 nucleos(t)ide analogue(NA)-naive patients with genotype C chronic hepatitis B(CHB).All patients without GR received LdT 600 mg once a day for 52 weeks.ALT levels and the quantity of hepatitis B surface antigen(HBsAg),HBeAg,and HBV DNA(COBAS TaqMan,lower limit of detection 300 copies/ml)were determined and analyzed at the baseline and at three-month intervals during therapy.Genotypic resistance was examined in weeks 36 and 52 by direct sequencing in patients with HBV DNA 1 000 copies/ml in week 52.Results Forty patients finished the 52-week treatment.At the end of the study,HBV DNA was not detected(HBV DNA 300 copies/ml) in 21 patients(52.5%)and HBV DNA 1 000 copies/ml in 16(40.0%).HBeAg seroconversion was achieved in three patients(7.5%).Ten patients(25%)developed drug resistance.Of these,two had the rtA181T mutation,seven had the rtM204I mutation,and 1 had the rtM204I and rtL180M mutations.Conclusion NA-naive patients with CHB treated with LdT were more likely to develop GR.This was particularly true for patients with higher HBV DNA levels at the baseline.GR to LdT involved one or more mutations,the most prevalent of which was the rtM204I mutation.
作者 高淑春 崔蕾 耿大影 张立新 陈士俊 GAO Shu-chun,CUI Lei,GENG Da-ying,ZHANG Li-xin,CHEN Shi-jun(Jinan Infectious Disease Hospital Affiliated with Shandong University,Jinan 250021,China)
出处 《中国病原生物学杂志》 CSCD 北大核心 2012年第10期774-777,共4页 Journal of Pathogen Biology
关键词 肝炎病毒 乙型 耐药分析 变异 替比夫定 Hepatitis B chronic resistance analysis mutation telbivudine
作者简介 高淑春(1977-),女,硕士,主治医师。研究方向:病毒性肝炎。E—mail:gaoshuchun0531@126.com 【通讯作者】陈士俊,E-mail:csj7516@126.com
  • 相关文献

参考文献10

  • 1贾继东,李兰娟,.慢性乙型肝炎防治指南(2010年版)[J].中华肝脏病杂志,2011,19(1):13-24. 被引量:3030
  • 2Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B[J]. N Engl J Med, 2007, 357: 2576-88. 被引量:1
  • 3Liaw YF, Gane E, Leung N, et al. 2 Year GLOBE trial results, telbivudine is superior to lamivudine in patients with chronic hepa- titis B[J].Gastroenterology, 2009, 136: 486-95. 被引量:1
  • 4乙型肝炎病毒耐药专家委员会.乙型肝炎病毒耐药专家共识[J].中华实验和临床感染病杂志(电子版),2008(1):90-98. 被引量:40
  • 5Bzowe) N, Chan LYH, Lai CL. A randomized trial of telbivudine VS adefovir for HBeAg-positive chronic hepatitis B~ final 52 week results[J]. Hepatology, 2006, 44(Suppl 1): 563 a. 被引量:1
  • 6贾继东,侯金林,尹有宽,徐道振,谭德明,牛俊奇,周霞秋,王宇明,朱理珉,贺永文,任红,万谟彬,陈成伟,巫善明,陈亚岗,许家璋,王勤环,魏来,马红.替比夫定或拉米夫定抗乙型肝炎病毒的疗效预测探讨[J].中华肝脏病杂志,2007,15(5):342-345. 被引量:137
  • 7杨芳,王磊.慢性乙型肝炎替比夫定相关耐药突变15例回顾性分析[J].山东大学学报:医学版,2011,49(4):129-132. 被引量:4
  • 8Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of tel- bivudine' treatment of chronic hepatitis B[J]. J Hepatol, 2009, 51:11-20. 被引量:1
  • 9Yuen MF, Fong DY, Wong DK, et aL Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response[J].Hepatology, 2007, 46: 1695-703. 被引量:1
  • 10Chu CM, Hung SJ, Lin J, et al. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase Ievels[J].Am J Med, 2004, 116(12): 829- 34. 被引量:1

二级参考文献158

共引文献3188

同被引文献7

二级引证文献1

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈